A detailed history of Tower Research Capital LLC (Trc) transactions in Eledon Pharmaceuticals, Inc. stock. As of the latest transaction made, Tower Research Capital LLC (Trc) holds 1,532 shares of ELDN stock, worth $6,342. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,532
Previous 16,958 90.97%
Holding current value
$6,342
Previous $44,000 93.18%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$2.41 - $3.19 $37,176 - $49,208
-15,426 Reduced 90.97%
1,532 $3,000
Q2 2024

Aug 13, 2024

BUY
$1.57 - $3.12 $17,715 - $35,206
11,284 Added 198.87%
16,958 $44,000
Q1 2024

May 15, 2024

BUY
$1.54 - $2.13 $58 - $80
38 Added 0.67%
5,674 $11,000
Q4 2023

Feb 13, 2024

SELL
$1.12 - $1.86 $3,143 - $5,221
-2,807 Reduced 33.25%
5,636 $10,000
Q3 2023

Nov 14, 2023

SELL
$1.14 - $1.66 $3,427 - $4,991
-3,007 Reduced 26.26%
8,443 $11,000
Q2 2023

Aug 14, 2023

BUY
$1.34 - $2.85 $6,966 - $14,817
5,199 Added 83.17%
11,450 $15,000
Q1 2023

May 09, 2023

BUY
$2.0 - $3.46 $8,706 - $15,061
4,353 Added 229.35%
6,251 $15,000
Q4 2022

Feb 10, 2023

BUY
$2.17 - $2.75 $2,729 - $3,459
1,258 Added 196.56%
1,898 $4,000
Q3 2022

Nov 10, 2022

SELL
$2.45 - $3.88 $967 - $1,532
-395 Reduced 38.16%
640 $1,000
Q2 2022

Aug 15, 2022

SELL
$2.34 - $3.96 $680 - $1,152
-291 Reduced 21.95%
1,035 $3,000
Q1 2022

May 12, 2022

SELL
$3.06 - $4.89 $2,233 - $3,569
-730 Reduced 35.51%
1,326 $5,000
Q4 2021

Feb 14, 2022

BUY
$4.02 - $6.07 $8,265 - $12,479
2,056 New
2,056 $9,000
Q3 2021

Nov 15, 2021

SELL
$5.94 - $8.46 $3,819 - $5,439
-643 Closed
0 $0
Q2 2021

Aug 16, 2021

BUY
$7.62 - $11.75 $4,899 - $7,555
643 New
643 $5,000

Others Institutions Holding ELDN

About Eledon Pharmaceuticals, Inc.


  • Ticker ELDN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 13,756,800
  • Market Cap $57M
  • Description
  • Eledon Pharmaceuticals, Inc., clinical stage biopharmaceutical company, focuses on developing medicines for the patients living with autoimmune disease and amyotrophic lateral sclerosis (ALS), and requiring an organ or cell-based transplant. Its lead product candidate includes AT-1501, a humanized monoclonal antibody to target CD40 Ligand that i...
More about ELDN
Track This Portfolio

Track Tower Research Capital LLC (Trc) Portfolio

Follow Tower Research Capital LLC (Trc) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Tower Research Capital LLC (Trc), based on Form 13F filings with the SEC.

News

Stay updated on Tower Research Capital LLC (Trc) with notifications on news.